These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20537787)

  • 1. Re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperberg, et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;57:622-30.
    Ost P; Bossi A; De Meerleer G
    Eur Urol; 2010 Sep; 58(3):e33; author reply e34-5. PubMed ID: 20537787
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.
    Semjonow A
    Eur Urol; 2010 Apr; 57(4):629-30. PubMed ID: 19375846
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment on: prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.
    Ciatto S
    Eur Urol; 2010 Apr; 57(4):630. PubMed ID: 19375847
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Martin Spahn, Steven Joniau, Paolo Gontero, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 2010;58:1-7.
    Neulander EZ; Wejsman Z
    Eur Urol; 2010 Sep; 58(3):e36; author reply e37-8. PubMed ID: 20605673
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Felix K.-H. Chun, Thomas Steuber, Andreas Erbersdobler, et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006;49:820-26.
    Beckley I; Khan MA
    Eur Urol; 2007 Oct; 52(4):1270; author reply 1271. PubMed ID: 17611016
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy.
    Hong SK; Park HZ; Lee WK; Kim DS; Lee JS; Doo SH; Jeong SJ; Yoon CY; Byun SS; Lee SE
    Urology; 2010 Sep; 76(3):723-7. PubMed ID: 20579699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy.
    Nakamura M; Hasumi H; Miyoshi Y; Sugiura S; Fujinami K; Yao M; Kubota Y; Uemura H
    Int J Urol; 2005 Dec; 12(12):1050-4. PubMed ID: 16409609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
    Doherty AP; Bower M; Smith GL; Miano R; Mannion EM; Mitchell H; Christmas TJ
    Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
    Stephan C; Schnorr D; Loening SA; Jung K
    Eur Urol; 2005 Dec; 48(6):1059-60; author reply 1060-1. PubMed ID: 16260082
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy: C. Von Bodman, G. Godoy, D. C. Chade, A. Cronin, L. J. Tafe, S. W. Fine, V. Laudone, P. T. Scardino and J. A. Eastham J Urol 2010; 184: 143-148.
    Cai T; Nesi G; Malossini G; Bartoletti R
    J Urol; 2011 Jan; 185(1):360-1; author reply 361. PubMed ID: 21092995
    [No Abstract]   [Full Text] [Related]  

  • 11. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy.
    Taylor JA; Koff SG; Dauser DA; McLeod DG
    BJU Int; 2006 Sep; 98(3):540-3. PubMed ID: 16925750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.
    McDonald MW
    J Urol; 1998 Oct; 160(4):1442. PubMed ID: 9751386
    [No Abstract]   [Full Text] [Related]  

  • 13. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
    Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
    Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
    Haese A; Huland E; Graefen M; Hammerer P; Noldus J; Huland H
    J Urol; 1999 Apr; 161(4):1206-11. PubMed ID: 10081870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
    Sengupta S; Christensen CM; Zincke H; Slezak JM; Leibovich BC; Bergstralh EJ; Myers RP; Blute ML
    J Urol; 2006 Aug; 176(2):559-63. PubMed ID: 16813889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.
    Chang SL; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
    Urology; 2010 Feb; 75(2):439-44. PubMed ID: 19819536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Aurélien Descazeaud, Marc Zerbib, Thierry Flam et al. Can pT0 stage of prostate cancer be predicted before radical prostatectomy? Eur Urol 2006;50:1248-53.
    Montironi R; Scarpelli M; Lopez-Beltran A; Cheng L
    Eur Urol; 2007 Jul; 52(1):294-5. PubMed ID: 17383812
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Monique J. Roobol, Ewout W. Steyerberg, Ries Kranse, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85.
    Morrod D
    Eur Urol; 2010 Sep; 58(3):327; author reply 328-30. PubMed ID: 20598799
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. B. J. Trock, C. C. Guo, M. L. Gonzalgo, A. Magheli, S. Loeb and J. I. Epstein. J Urol 2009; 182: 1364-1370.
    Ikenberg K; Zimmermann AK; Kristiansen G
    J Urol; 2010 May; 183(5):2100; author reply 2100-1. PubMed ID: 20359717
    [No Abstract]   [Full Text] [Related]  

  • 20. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
    Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.